Clearmind Medicine announced a Hong Kong patent application for psychedelic compounds to treat PTSD and related disorders.
Quiver AI Summary
Clearmind Medicine Inc., a clinical-stage biopharmaceutical company based in Vancouver, has announced the publication of a Hong Kong patent application for innovative psychedelic compounds designed to treat Post-Traumatic Stress Disorder (PTSD) and other mental health issues. This application is part of an exclusive licensing agreement with Yissum Research Development Company of the Hebrew University of Jerusalem, which gives Clearmind global rights to develop and commercialize these novel compounds. The company is focusing on non-hallucinogenic psychedelic-derived neuroplastogens to address neuropsychiatric disorders, including Alcohol Use Disorder. The global market for PTSD therapeutics was valued at approximately $19 billion in 2025 and is expected to reach $24.8 billion by 2030, indicating strong potential for these new treatment options. Clearmind currently holds an extensive intellectual property portfolio and plans to continue seeking patent protection for its innovative therapeutic candidates.
Potential Positives
- Publication of a Hong Kong patent application for innovative psychedelic compounds targeting PTSD and other mental health disorders enhances Clearmind's intellectual property portfolio.
- Exclusive worldwide licensing agreement with Yissum Research Development Company provides Clearmind with global rights to develop and commercialize novel therapeutic compounds.
- Market research indicates substantial growth potential in the PTSD therapeutics market, projected to reach approximately $24.8 billion by 2030, showcasing significant commercial opportunities for Clearmind's products.
- The company's commitment to continue building its intellectual property portfolio, including current holdings of 19 patent families and 32 granted patents, reflects a strong foundation for innovation and market presence.
Potential Negatives
- The press release emphasizes that forward-looking statements made by the company are inherently uncertain, indicating potential risks in achieving the projected outcomes.
- There is no guarantee that the pending patent will be granted, nor that it will be beneficial if it is issued, which raises concerns about the strength of the company’s intellectual property position.
- The company discloses reliance on market research, yet it does not provide clear evidence of its own competitive advantage, which may raise questions about its market positioning in the rapidly growing PTSD therapeutics market.
FAQ
What recent patent did Clearmind Medicine announce?
Clearmind announced a Hong Kong patent application covering innovative psychedelic compounds for treating Post-Traumatic Stress Disorder (PTSD).
What is the focus of Clearmind Medicine?
Clearmind focuses on developing non-hallucinogenic psychedelic-derived neuroplastogens for neuropsychiatric and addiction disorders, including Alcohol Use Disorder.
How does the new patent application affect Clearmind's portfolio?
The new patent application expands Clearmind's global portfolio for PTSD-focused psychedelic compounds, enhancing their intellectual property protections.
What is the projected growth of the PTSD therapeutics market?
The global PTSD therapeutics market is projected to grow from approximately $19 billion in 2025 to $24.8 billion by 2030.
Where is Clearmind Medicine listed for trading?
Clearmind Medicine is listed for trading on Nasdaq under the symbol "CMND."
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$CMND Insider Trading Activity
$CMND insiders have traded $CMND stock on the open market 5 times in the past 6 months. Of those trades, 1 have been purchases and 4 have been sales.
Here’s a breakdown of recent trading of $CMND stock by insiders over the last 6 months:
- FINANCIAL LP HRT has made 1 purchase buying 2,159,052 shares for an estimated $330,334 and 4 sales selling 252,615 shares for an estimated $118,520.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
$CMND Hedge Fund Activity
We have seen 5 institutional investors add shares of $CMND stock to their portfolio, and 3 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- CITADEL ADVISORS LLC added 14,883 shares (+1016.6%) to their portfolio in Q3 2026, for an estimated $95,859
- HRT FINANCIAL LP removed 4,393 shares (-100.0%) from their portfolio in Q3 2026, for an estimated $28,294
- JANE STREET GROUP, LLC added 3,966 shares (+inf%) to their portfolio in Q3 2026, for an estimated $25,544
- XTX TOPCO LTD added 1,410 shares (+inf%) to their portfolio in Q3 2026, for an estimated $9,081
- UBS GROUP AG added 703 shares (+inf%) to their portfolio in Q3 2026, for an estimated $4,527
- MORGAN STANLEY removed 88 shares (-100.0%) from their portfolio in Q3 2026, for an estimated $566
- ROYAL BANK OF CANADA removed 36 shares (-100.0%) from their portfolio in Q3 2026, for an estimated $231
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
Full Release
Vancouver, Canada, Nov. 19, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmind” or the “Company”), a clinical-stage biopharmaceutical company advancing non-hallucinogenic psychedelic-derived neuroplastogens for scalable treatment of neuropsychiatric, metabolic, and addiction disorders including Alcohol Use Disorder (“AUD”), today announced the publication of a Hong Kong patent application covering innovative psychedelic compounds targeting the treatment of Post-Traumatic Stress Disorder (“PTSD”) and other mental health disorders.
The patent application is part of the Company's exclusive worldwide licensing agreement with Yissum Research Development Company of the Hebrew University of Jerusalem (“Yissum”). The compounds were invented by Professors Ahmed Masaewa, Rami Yaka, and Avi Priel of the Hebrew University. Under the licensing agreement, Clearmind holds exclusive global rights to develop, manufacture, and commercialize the novel compounds.
The Hong Kong patent publication expands Clearmind's global patent application portfolio for its proprietary PTSD-focused psychedelic compounds. Together with existing international filings, the application supports the Company's strategy to seek intellectual property protection for its novel therapeutic candidates across major global markets.
According to market research by Heimdall Insights, the global PTSD therapeutics market was valued at approximately $19 billion in 2025 and is projected to reach $24.8 billion by 2030 , representing a compound annual growth rate (CAGR) of approximately 5.5%. In addition, GlobalData projects that the PTSD pharmaceutical market across seven major markets is projected to grow from $1.2 billion in 2024 to $5.5 billion by 2034 , at a CAGR of 16.1%, reflecting anticipated demand for innovative treatment options.
About Clearmind Medicine Inc.
Clearmind is a clinical-stage neuroplastogens pharmaceutical biotech company focused on the discovery and development of non-hallucinogenic, second generation, neuroplastogen-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods, or supplements.
The Company’s intellectual property portfolio currently consists of nineteen patent families, including 32 granted patents. The Company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.
Shares of Clearmind are listed for trading on Nasdaq under the symbol "CMND."
For further information, visit: https://www.clearmindmedicine.com or contact:
Investor Relations
[email protected]
www.Clearmindmedicine.com
Forward-Looking Statements:
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act and other securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, the Company is using forward-looking statements when it discusses the potential of the novel compounds covered by the patent application; the Company's ability to develop, manufacture, and commercialize such compounds; the potential commercial opportunities associated with such compounds; the Company's strategy to seek intellectual property protection for its novel therapeutic candidates across key global markets; and expected growth in the PTSD pharmaceutical market. The Company cannot assure that any patent will issue as a result of a pending patent application or, if issued, whether it will issue in a form that will be advantageous to the Company. Forward-looking statements are not historical facts, and are based upon management’s current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management’s expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company’s reports filed from time to time with the Securities and Exchange Commission (“SEC”), including, but not limited to, the risks detailed in the Company’s annual report on Form 20-F for the fiscal year ended October 31, 2025 and subsequent filings with the SEC. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Clearmind is not responsible for the contents of third-party websites.